Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Type 1 Diabetes Cases In Children Under Five To Double By 2020
Cases of type 1 diabetes in children under five years across Europe will double by 2020 (from 2005 levels) if present trends continue. Numbers in children older than five will also increase substantially. The findings are discussed in an Article published Online First and in an upcoming edition of The Lancet, written by Dr Chris Patterson, Queen"s University, Belfast, UK, and Prof Gyula Soltç©sz, Pç©cs University, Pç©cs, Hungary, and colleagues.

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression Of Structural Joint Damage In Rheumatoid Arthritis Patients
One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a significant inhibition in the progression of structural joint damage compared with patients treated with methotrexate alone. These data will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark, along with additional studies that support the use of ACTEMRA as a long-term treatment option for patients with moderately to severely active RA.
News of the day
Shedding Light On Preserving Fertility Among Cancer Patients
Cancer treatment has come a long way, leading to a multitude of therapy options and improved survival rates. These successes, however, have created a challenge for young cancer patients since chemotherapy and radiation treatments that often save lives threaten fertility. Techniques available to safeguard fertility, such as freezing eggs for later embryo development, have poor odds of success, leaving patients with very limited options for the future. But that is beginning to change as researchers improve current techniques, mature human eggs in the laboratory, and discover cellular mechanisms that could help preserve and even restore fertility. Researchers will report on these and other findings at the 42nd annual meeting of the Society for the Study of Reproduction (SSR), July 18 to 22, at the David L. Lawrence Convention Center in Pittsburgh.
Cardiovascular

NPS RADAR Reviews Rivaroxaban - Oral Anticoagulant For Post-knee Replacement Surgery, Australia

Prescribers treating patients who have had total hip or knee replacement surgery can access an independent review of the oral anticoagulant rivaroxaban (Xarelto) in the August issue of NPS RADAR. NPS RADAR provides independent information about new medicines and changes to PBS listings to health professionals and is published to coincide with PBS updates, giving health professionals access to information when they need it. "GPs and pharmacists may see patients who have been initiated on rivaroxaban in hospital. They should be aware that rivaroxaban has only been evaluated for use in preventing deep vein thrombosis and pulmonary embolism after elective total hip or total knee replacement surgery," NPS senior adviser, quality use of medicines, Judith Mackson said. "Duration of the therapy is 14 days after knee replacement or 35 days after hip replacement and no longer. Some patients will need a GP prescription soon after discharge to cover the remaining duration of therapy. GPs will need to take into account the number of tablets the hospital has provided when selecting a suitable pack size and instructing the patient on how many tablets to take." Dose adjustment and titration, and monitoring of prothrombin time are not required. As with other anticoagulants, managing the risk of bleeding is a primary concern, and patients should be alert to possible signs of bleeding. "Prescribers should be aware that there are only small differences in efficacy and safety between rivaroxaban, low molecular weight heparins (Clexane and Fragmin), fondaparinux (Arixtra) and dabigatran (Pradaxa)," Ms Mackson said. Other topics covered in the latest edition of NPS RADAR include: - Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain - Oxybutynin patch (Oxytrol) PBS listed as an alternative for overactive bladder - Update on PBS listings for Aboriginal peoples and Torres Strait Islanders - Sitagliptin with metformin - (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus - Risedronate (Actonel Once-a-month) and summary of anti-resorptive drug listings - Lanthanum (Fosrenol) tablets for adults with chronic kidney disease who are on dialysis http://www.nps.org.au/radar National Prescribing Service.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009